Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Outset Medical (OM) Shares Outstanding (Weighted Average) (2018 - 2026)

Outset Medical has reported Shares Outstanding (Weighted Average) over the past 8 years, most recently at $15211.0 for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 339.24% to $15211.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15211.0 through Dec 2025, up 339.24% year-over-year, with the annual reading at $15211.0 for FY2025, 339.24% up from the prior year.
  • Shares Outstanding (Weighted Average) was $15211.0 for Q4 2025 at Outset Medical, down from $17783.0 in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $379000.0 in Q1 2025 and troughed at $3305.0 in Q4 2023.
  • The 5-year median for Shares Outstanding (Weighted Average) is $45966.0 (2021), against an average of $66356.2.
  • Year-over-year, Shares Outstanding (Weighted Average) crashed 99.62% in 2021 and then soared 11070.06% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $45589.0 in 2021, then rose by 5.64% to $48161.0 in 2022, then tumbled by 93.14% to $3305.0 in 2023, then rose by 4.78% to $3463.0 in 2024, then skyrocketed by 339.24% to $15211.0 in 2025.
  • Per Business Quant, the three most recent readings for OM's Shares Outstanding (Weighted Average) are $15211.0 (Q4 2025), $17783.0 (Q3 2025), and $379000.0 (Q2 2025).